DE69520376T2 - Ein hydrophobisches sulfolipidisches polysaccharid enthaltendes adjuvans für impfstoffe - Google Patents

Ein hydrophobisches sulfolipidisches polysaccharid enthaltendes adjuvans für impfstoffe

Info

Publication number
DE69520376T2
DE69520376T2 DE69520376T DE69520376T DE69520376T2 DE 69520376 T2 DE69520376 T2 DE 69520376T2 DE 69520376 T DE69520376 T DE 69520376T DE 69520376 T DE69520376 T DE 69520376T DE 69520376 T2 DE69520376 T2 DE 69520376T2
Authority
DE
Germany
Prior art keywords
vaccine
sulfolipidic
adjuvan
hydrophobic
polysaccharide containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69520376T
Other languages
English (en)
Other versions
DE69520376D1 (de
Inventor
Luuk Hilgers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer AG
Original Assignee
Dimminaco AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3888560&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69520376(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dimminaco AG filed Critical Dimminaco AG
Publication of DE69520376D1 publication Critical patent/DE69520376D1/de
Application granted granted Critical
Publication of DE69520376T2 publication Critical patent/DE69520376T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69520376T 1994-12-27 1995-12-21 Ein hydrophobisches sulfolipidisches polysaccharid enthaltendes adjuvans für impfstoffe Expired - Lifetime DE69520376T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BE9401174A BE1008978A5 (fr) 1994-12-27 1994-12-27 Adjuvants pour vaccins.
PCT/BE1995/000119 WO1996020008A1 (fr) 1994-12-27 1995-12-21 Adjuvants pour vaccins

Publications (2)

Publication Number Publication Date
DE69520376D1 DE69520376D1 (de) 2001-04-19
DE69520376T2 true DE69520376T2 (de) 2001-08-09

Family

ID=3888560

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69520376T Expired - Lifetime DE69520376T2 (de) 1994-12-27 1995-12-21 Ein hydrophobisches sulfolipidisches polysaccharid enthaltendes adjuvans für impfstoffe
DE69531699T Expired - Lifetime DE69531699T2 (de) 1994-12-27 1995-12-21 Cyclodextrinderivate und verfahren zu deren herstellung

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69531699T Expired - Lifetime DE69531699T2 (de) 1994-12-27 1995-12-21 Cyclodextrinderivate und verfahren zu deren herstellung

Country Status (17)

Country Link
US (2) US6328965B1 (de)
EP (2) EP0800539B1 (de)
JP (2) JP3927235B2 (de)
CN (2) CN1132630C (de)
AT (2) ATE199644T1 (de)
AU (2) AU713997B2 (de)
BE (1) BE1008978A5 (de)
BR (2) BR9510223A (de)
CA (2) CA2208849C (de)
DE (2) DE69520376T2 (de)
DK (2) DK0800539T3 (de)
ES (2) ES2155540T3 (de)
GR (1) GR3035941T3 (de)
MX (1) MX9704822A (de)
PT (2) PT800539E (de)
SI (1) SI0800539T1 (de)
WO (2) WO1996020008A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1008978A5 (fr) * 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.
US5916883A (en) * 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
EP1009429B1 (de) * 1997-08-29 2009-07-08 Antigenics Inc. Adjuvant qs-21 enthaltende zusammensetzungen mit polysorbate oder cyclodextrin als hilfsmittel
EP1104767A1 (de) * 1999-11-30 2001-06-06 Stichting Dienst Landbouwkundig Onderzoek Mono- und Disaccharidederivate die sowohl Fettsäureestern als Sulfatestern enthalten
AT408150B (de) * 2000-04-14 2001-09-25 Oesterr Forsch Seibersdorf Verfahren zur immobilisierung eines analyten an einer festen oberfläche
FR2808691B1 (fr) * 2000-05-12 2005-06-24 Coletica Cyclodextrines substituees preferentiellement sur leur face primaire par des fonctions acide ou amine
FR2825714B1 (fr) * 2001-06-08 2005-03-25 Seppic Sa Nouvelle utilisation de complexes d'inclusion de cyclodestrine
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
WO2003086283A2 (en) * 2002-04-09 2003-10-23 Greenville Hospital System Metastasis modulating activity of highly sulfated oligosaccharides
JP5021309B2 (ja) * 2003-10-16 2012-09-05 ステファン ジョン ラルフ 免疫調節性組成物およびその使用方法
CN101355952B (zh) 2005-11-28 2012-03-21 韦罗制药有限公司 用于减少肾毒性的组合物及其使用方法
US20090017064A1 (en) * 2007-07-10 2009-01-15 Wyeth Methods and Compositions for Immunizing Pigs Against Porcine Circovirus
KR101225304B1 (ko) 2007-11-06 2013-01-22 와이어쓰 엘엘씨 마이코플라스마 하이오뉴모니아에 비독성 항원보강된 살아있는 백신
EP2062594A1 (de) * 2007-11-21 2009-05-27 Wyeth Farma, S.A. Impfstoff und immunogene Zusammensetzung gegen den Blauzungenvirus, Verfahren zu deren Verwendung und Verfahren zu deren Herstellung
US8192721B2 (en) * 2007-12-13 2012-06-05 Verrow Pharmaceuticals, Inc. Compositions useful for reducing toxicity associated with gadolinium-based contrast agents
MX2012000044A (es) 2009-06-22 2012-01-30 Wyeth Llc Composiciones inmunogenicas de antigenos de staphylococcus aureus.
EP3461496B1 (de) 2009-06-22 2023-08-23 Wyeth LLC Zusammensetzungen und verfahren zur herstellung von staphylococcus aureus serotyp-5 und 8-kapselpolysaccharid-konjugat-immunogenzusammensetzungen
US20110110980A1 (en) * 2009-09-02 2011-05-12 Wyeth Llc Heterlogous prime-boost immunization regimen
EP2397484A1 (de) 2010-06-11 2011-12-21 Immunovo B.V. Trisaccharidderivate und ihre Verwendung als Adjuvantien
PT3246044T (pt) 2010-08-23 2021-02-15 Wyeth Llc Formulações estáveis de antigénios de rlp2086 de neisseria meningitidis
NZ607224A (en) 2010-09-10 2014-11-28 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
CN101972477B (zh) * 2010-10-21 2012-09-26 中国医学科学院医学生物学研究所 磷酸锌疫苗佐剂
ES2614815T3 (es) 2010-12-22 2017-06-02 Wyeth Llc Composiciones inmunogénicas estables de antígenos de Staphylococcus aureus
NZ628449A (en) 2012-03-09 2016-04-29 Pfizer Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
UA114503C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
PL3363806T3 (pl) 2012-12-20 2022-12-19 Pfizer Inc. Sposób glikokoniugacji
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
EP4098276A1 (de) 2013-09-08 2022-12-07 Pfizer Inc. Neisseria meningitidis-zusammensetzungen und verfahren dafür
JP6821429B2 (ja) 2013-09-25 2021-01-27 ゾエティス・サービシーズ・エルエルシー Ｐｃｖ２ｂ分岐ワクチン組成物及び使用方法
CN104013955B (zh) * 2014-06-18 2016-02-24 中国科学院过程工程研究所 一种不含表面活性剂的水包油乳液及其用途
CN104086676B (zh) * 2014-07-18 2017-01-25 江苏省农业科学院 一种环糊精酯化衍生物、制备方法及其应用
LT3193923T (lt) 2014-07-24 2019-12-10 Litevax B V Adjuvantai
KR20170103009A (ko) 2015-02-19 2017-09-12 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
IL255106B2 (en) 2015-05-04 2023-04-01 Pfizer Protein-polysaccharide conjugates of group b streptococcus, methods for preparing conjugates, immunogenic preparations containing conjugates and their uses
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
CN118021947A (zh) 2017-01-31 2024-05-14 辉瑞大药厂 脑膜炎奈瑟菌组合物及其使用方法
CN106928378A (zh) * 2017-03-29 2017-07-07 中国药科大学 一种十二酰基‑β‑环糊精的制备方法和用于色氨酸手性拆分的聚砜膜的制备方法
EP3765069A1 (de) 2018-03-16 2021-01-20 Zoetis Services LLC Peptid-vakzine gegen interleukin-31
EP4203995A1 (de) 2020-08-26 2023-07-05 Pfizer Inc. Gruppe-b-streptococcus-polysaccharid-protein-konjugate, verfahren zur herstellung von konjugaten, immunogene zusammensetzungen mit konjugaten und verwendungen davon

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3565887A (en) * 1968-05-15 1971-02-23 Corn Products Co Unsaturated and long chain esters of cyclodextrin
US4247535A (en) * 1979-11-05 1981-01-27 American Cyanamid Company Modified cyclodextrin sulfate salts as complement inhibitors
US5760015A (en) * 1988-01-19 1998-06-02 The Trustees Of The University Of Pennsylvania Cyclodextrin compounds and methods of making and use thereof
US5658894A (en) * 1989-04-23 1997-08-19 The Trustees Of The University Of Pennsylvania Compositions for inhibiting restenosis
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
EP0518930A4 (en) * 1990-03-02 1993-09-15 Australian Commercial Research & Development Limited Cyclodextrin compositions and methods for pharmaceutical and industrial applications
FR2672496B3 (fr) * 1990-07-18 1993-05-28 Vacsyn France Sa Compositions a base de substances hydrophobes, solubilisables dans un solvant aqueux, leur procede d'obtention, et leurs utilisations notamment dans le domaine pharmaceutique.
US5180716A (en) * 1990-08-01 1993-01-19 The Regents Of The University Of California Cyclodextrin complexes for neuraxial administration of drugs
IT1242214B (it) * 1990-11-13 1994-03-03 Emo Chiellini Derivati polifunzionali delle ciclodestrine
JP2556236B2 (ja) * 1991-08-29 1996-11-20 田辺製薬株式会社 β−シクロデキストリン誘導体のポリ硫酸エステル及びその製法
ZA929870B (en) * 1991-12-23 1993-08-18 Duphar Int Res Adjuvants
WO1993017711A1 (en) * 1992-03-11 1993-09-16 Australian Commercial Research & Development Limited New cyclodextrins and new formulated drugs
DE4220734A1 (de) * 1992-06-25 1994-01-05 Puetter Medice Chem Pharm Lipophile Cyclodextrinpolymere
US5464827A (en) * 1994-06-20 1995-11-07 American Home Products Corporation Esterified polyanionic cyclodextrins as smooth muscle cell proliferation inhibitors
BE1008978A5 (fr) * 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.

Also Published As

Publication number Publication date
AU713997B2 (en) 1999-12-16
ATE248863T1 (de) 2003-09-15
DE69531699T2 (de) 2004-07-08
CN1175264A (zh) 1998-03-04
AU709104B2 (en) 1999-08-19
BR9510223A (pt) 1997-12-30
CN1171052A (zh) 1998-01-21
AU4324996A (en) 1996-07-19
BR9510263A (pt) 1997-11-04
DK0800539T3 (da) 2003-12-08
MX9704822A (es) 1998-05-31
GR3035941T3 (en) 2001-08-31
BE1008978A5 (fr) 1996-10-01
US6165995A (en) 2000-12-26
JPH11502192A (ja) 1999-02-23
EP0814836A1 (de) 1998-01-07
DE69520376D1 (de) 2001-04-19
EP0814836B1 (de) 2001-03-14
PT800539E (pt) 2004-01-30
CA2208849A1 (en) 1996-07-04
CN1109049C (zh) 2003-05-21
CA2208849C (en) 2006-10-10
ES2155540T3 (es) 2001-05-16
CN1132630C (zh) 2003-12-31
JPH10511997A (ja) 1998-11-17
JP3927235B2 (ja) 2007-06-06
DK0814836T3 (da) 2001-04-17
SI0800539T1 (en) 2003-12-31
CA2208790A1 (en) 1996-07-04
EP0800539B1 (de) 2003-09-03
EP0800539A1 (de) 1997-10-15
MX9704824A (es) 1998-06-30
JP4087900B2 (ja) 2008-05-21
ES2204969T3 (es) 2004-05-01
WO1996020008A1 (fr) 1996-07-04
CA2208790C (en) 2012-01-31
US6328965B1 (en) 2001-12-11
AU4324896A (en) 1996-07-19
ATE199644T1 (de) 2001-03-15
WO1996020222A1 (en) 1996-07-04
DE69531699D1 (de) 2003-10-09
PT814836E (pt) 2001-07-31

Similar Documents

Publication Publication Date Title
DE69520376T2 (de) Ein hydrophobisches sulfolipidisches polysaccharid enthaltendes adjuvans für impfstoffe
ES2109929T3 (es) Procedimiento para preparar un glucano de levadura
PT91856A (pt) Processo de preparacao de uma matriz com actividade imunomodulante, a base lipido e saponina
DE69529684T2 (de) Adjuvans für impfstoff
EA200000711A1 (ru) 11β-ГАЛОГЕН-7α-ЗАМЕЩЕННЫЕ ЭСТРАТРИЕНЫ, СПОСОБ ПОЛУЧЕНИЯ ФАРМАЦЕВТИЧЕСКИХ ПРЕПАРАТОВ, СОДЕРЖАЩИХ ЭТИ 11β-ГАЛОГЕН-7α-ЗАМЕЩЕННЫЕ ЭСТРАТРИЕНЫ, И ИХ ПРИМЕНЕНИЕ ДЛЯ ИЗГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ
PT98156A (pt) Um processo de preparacao de uma composicao de vacina
ATE105181T1 (de) Verfahren zur herstellung einer oel-in-wasseremulsion eines wirkstoffes.
ES2037742T3 (es) Procedimiento de obtencion de una composicion para administracion intravenosa.
DE59006868D1 (de) 2-Alkyl-4-arylmethylaminochinoline, ihre Verwendung und daraus hergestellte Arzneimittel.
ES2062805T3 (es) Procedimiento para la preparacion de sulfatos ciclicos.
ES2119779T3 (es) Solubilizacion de proteinas en formas activas.
EP0527977A4 (en) Nematode vaccine
HUP9801917A2 (hu) Immunogén készítmény, eljárás annak előállítására és vakcinaként történő alkalmazására
ES2146279T3 (es) 1-ciclopropiltetrazolinonas herbicidas.
ES2054281T3 (es) Disoluciones de pentamidina.
NZ511118A (en) Activation of cellular immunity with antigenic proteins and hydrophobized polysaccharides, which have modified alkyl or cholesterol groups
Hayashi et al. A Survey on the Sex Difference for Truck-Driver
AR246955A1 (es) Metodo para la preparacion de clorhidrato del acido ¡ ¡ ¡ ¡ ¡
M Shoukry Visual damage, clinical course and visual prognosis in capsular glaucoma and simplex glaucoma
ES2042198T3 (es) Un marco.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: PFIZER AG, ZUERICH, CH